With AI-BIO

WHO WE ARE

History

  • 2018

    • 04

      Establishment of Baobab Pharm Co., Ltd. at Yonsei University Seoul Korea

    • 04

      Inauguration of CEO Kyoung Tai No

    • 07

      Selected for a National grant of Bio-SPC for development of therapeutic agents by Ministry of Science & ICT

  • 2019

    • 04

      Fund Raising 750M from Geno Focus

    • 11

      Inauguration of CEO In Sang Lee and CTO Kyoung Tai No(Each Representative)

  • 2020

    • 03

      Selected for BIG3(Bio, Health) Project by Ministry of SMEe and Startups

    • 04

      Move to Yonsei University International Campus at Songdo Inchon

    • 04

      Company name changed to BaobabAiBio Co., Ltd.

    • 04

      Establishment of Company R&D Center

    • 08

      Certified as a Venture Business Company

    • 10

      Selected for a National grant of Drug development of colon cancer and rare diseases using artificial intelligence platforms by Ministry of SMEs and Start Ups

    • 11

      Selected for a National grant of Development of AI platform based first-in-class drug design to overcome drug-resistance of melanoma patients by Ministry of SMEs and Start Ups

    • 12

      Series A Fund Raising 4.5B

  • 2021

    • 02

      Fund Raising

    • 03

      Series A Fund Raising 11.5B

    • 05

      Establishment of Gwang-Ju Branch

    • 05

      Research service contract with eFlask

    • 06

      Research service contract with MirimGene

    • 09

      Research service contract with Jeil Pharma

    • 12

      Set up Cryo-EM systems Aquilos2, Glacios(200K), Krios(300K)